trimebutin | Trimedat tablets 200 mg, 30 pcs.

Latin name

TRIMEDAT

release form

tablets

Packing

30 pcs

Pharmacological action

Trimedat - normalizing intestinal motility, normalizing the function of the digestive tract.

Pharmacodynamics

Trimebutin, acting on the intestinal enkephalinergic system, is a regulator of its peristalsis. With an affinity for excitation and suppression receptors, It has a stimulating effect in hypokinetic states of smooth muscles of the intestine and antispasmodic in hyperkinetic.

The drug acts throughout the gastrointestinal tract, reduces the tone of the sphincter of the esophagus, promotes emptying of the stomach and enhances intestinal motility, and also contributes to the response of smooth muscles of the colon to food irritants. Trimebutin restores the normal physiological activity of intestinal muscles in various diseases of the gastrointestinal tract associated with impaired motility.

Pharmacokinetics

After oral administration, trimebutin is rapidly absorbed from the digestive tract. Tmax in blood plasma - 1-2 hours. Bioavailability is 4-6%. Vd - 88 l.

The degree of binding to plasma proteins is low - about 5%. Trimebutin to a small extent penetrates the placental barrier.

Metabolism and excretion. Trimebutin is biotransformed in the liver and excreted in the urine mainly in the form of metabolites (approximately 70% during the first 24 hours). T1 / 2 - about 12 hours

Indications

Disorders of the gastrointestinal tract in the following diseases and conditions:

gastroesophageal reflux disease

dyspeptic disorders in gastroduodenal diseases (abdominal pain, digestive disturbance, nausea, vomiting)

irritable bowel syndrome (manifested by pain, colic in the abdomen, intestinal cramps, flatulence, diarrhea and / or constipation)

postoperative paralytic intestinal obstruction

preparation for radiological / endoscopic examination of gastrointestinal dysplasia, srd associated with impaired gastrointestinal motility.

Contraindications

Hypersensitivity to the components of the drug

children under 3 years of age

pregnancy and lactation.

Use during pregnancy and lactation

The use of the drug Trimedat in the first trimester of pregnancy is not recommended.

The use of the drug Trimedat during breastfeeding is not recommended due to the lack of reliable clinical data confirming the safety of the drug.

In experimental studies, there was no evidence of teratogenicity and embryotoxicity of the drug.

Composition

1 tablet contains:

Active ingredient:

trimebutine maleate 200 mg

Excipients:

lactose,

silicon dioxide colloidal,

talc,

starch.

Dosage and administration of

Adults and children over 12 years of age: the drug is administered orally 100-200 mg 3 times a day.

To prevent relapse of irritable bowel syndrome after a course of treatment during the period of remission, it is recommended to continue taking the drug at a dose of 300 mg / day for 12 weeks.

For children aged 5-12 years: appoint 50 mg 3 times a day.

Children aged 3-5 years: 25 mg 3 times a day.

Side effects

Rarely: skin reactions.

Drug Interaction

There are no drug interaction data for Trimedat.

Overdose

There have been no reports of overdose with Trimedat so far.

Storage conditions

Store at a temperature not exceeding 25 РC.

Keep out of the reach of children.

Expiration

3 years.

Active ingredient

Trimebutin



pharmacy leave without a prescription

dosage form

dosage form

tablets

Valenta Pharma, Russia